Cardiology
New Real-World Data Published in Journal of Cardiac Failure on Effectiveness
August 6, 2024Research and Development Cardiac, Cardiology, Pfizer
Patients treated with tafamidis were associated with greater rates of survival compared with patients untreated with tafamidis. Walton Oaks, 6th August …
ApoC3 targeted by Sirnaomics through its announced completion of IND-Enabling studies of safety and efficacy for STP125G with NHP Models
July 15, 2024Research and Development Cardiology, RNAi therapeutics, Sirnaomics, biopharmaceutical, cardiovascular, investigational new drug
Sirnaomics, a biopharmaceutical company engaging in discovery and development of advanced RNAi therapeutics, has announced the completion of IND-enabling studies …
OSE Immunotherapeutics and Boehringer Ingelheim collaborate on cancer and cardio-renal-metabolic disease treatments
May 24, 2024Research and Development Boehringer Ingelheim, Cancer, Cardiology, OSE Immunotherapeutics, cardio-renal-metabolic diseases
OSE Immunotherapeutics and Boehringer Ingelheim have announced a major expansion of their existing partnership. The expansion includes two new projects …
AstraZeneca adds new heart failure target through collaboration with BenevolentAI
May 15, 2024Research and Development AstraZeneca, BenevolentAI, Cardiology, collaboration, heart failure
BenevolentAI has announced that AstraZeneca has added a novel heart failure target to its discovery portfolio following the two companies’ …
NHS accepts Pfizer’s tafamidis for ATTR-CM treatment
May 14, 2024Medical Communications ATTR-CM, Cardiology, NHS, Pfizer, tafamidis
NHS England has announced that it has accepted Pfizer’s drug, tafamidis, for the treatment of transthyretin amyloidosis cardiomyopathy (ATTR-CM).
Verona Pharma to share phase 3 COPD trial data at ATS 2024
May 2, 2024Medical Communications COPD, Cardiology, clinical trial, verona pharma
Verona Pharma has announced that it will share eight posters at the American Thoracic Society International Conference (ATS) 2024, including …
Bayer and Evotec to collaborate on precision cardiology
April 30, 2024Research and Development Bayer, Cardiology, cardio, cvd
Bayer and Evotec have announced that they have updated the focus of their collaboration to work on the development of …
Sanofi shares results for phase 3 LUNA 3 trial in immune thrombocytopenia
April 23, 2024Research and Development Cardiology, Sanofi, clinical trial, thrombocytopenia
Sanofi has announced positive results from its phase 3 LUNA 3 study, which assessed rilzabrutinib 400mg twice daily oral treatment …
Johnson & Johnson to acquire Shockwave Medical
April 8, 2024Business Services Cardiology, Johnson & Johnson, Shockwave Medical, acquisition
Johnson & Johnson (J&J) and Shockwave Medical have announced that they have entered into a definitive agreement under which J&J …
FDA approves Eko Health’s AI for heart failure detection
April 3, 2024Medical Communications Cardiology, Eko Health, FDA, heart failure, low ejection fraction
Eko Health has announced that the US Food and Drug Administration (FDA) has approved its Low Ejection Fraction (Low EF) …
FDA approves Merck’s Winrevair for PAH treatment
March 27, 2024Medical Communications Cardiology, FDA, Merck, Winrevair, pulmonary arterial hypertension
Merck, known as MSD outside of the US and Canada, has announced that the US Food and Drug Administration (FDA) …
FDA approves J&J’s Opsynvi for PAH treatment
March 25, 2024Medical Communications Cardiology, FDA, J&J, Johnson & Johnson, Opsynvi, pulmonary arterial hypertension
Johnson & Johnson (J&J) has announced that the US Food and Drug Administration (FDA) has approved Opsynvi (macitentan and tadalafil) …
FDA approves Idorsia’s Tryvio for treatment of high blood pressure
March 22, 2024Medical Communications Cardiology, FDA, Tryvio, blood pressure, blood presure, hypertension
Idorsia has announced that the US Food and Drug Administration (FDA) has approved Tryvio (aprocitentan) for the treatment of hypertension …
Tenax Therapeutics enrolls first patient in phase 3 trial for pulmonary hypertension treatment
February 8, 2024Research and Development Cardiology, Tenax Therapeutics, clinical trial, pulmonary hypertension
Tenax Therapeutics has announced that it has enrolled the first patient in its phase 3 LEVEL study, which aims to …
AstraZeneca shares results from phase 3 trial of acoramidis in adults with ATTR-CM
February 2, 2024Research and Development ATTR-CM, AstraZeneca, Cardiology, acoramidis, clinical trial
AstraZeneca has announced positive high-level results from the phase 3 trial of acoramidis in adults with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM) …
Latest content
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions
